Intel 471 Releases Report to Help Europe’s Critical Entities Navigate the Network and Information Security Directive (NIS2)
5.11.2024 10:00:00 EET | Business Wire | Press release
Today, Intel 471, a global leader in cyber threat intelligence (CTI) and intelligence-driven solutions, released its new report, NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resiliency.The report offers key insights into how actionable CTI can help organisations navigate Europe’s new cybersecurity regulations, proactively mitigate digital risk, improve cyber resilience, and avoid penalties and fines.
National laws implementing the European Union’s NIS2 Directive (EU) 2022/2555 to lift the cyber resilience of critical infrastructure across Europe went into effect on 18 October 2024. NIS2 has dramatic implications for how important and essential operators of critical services manage cyber risks compared to its predecessor, NIS1, the 2016 Network and Information Systems Directive. It gives regulators wider supervisory powers, introduces higher standards for cyber risk management, mandatory incident reporting and tougher sanctions. If not followed, essential entities face administrative fines of up to €10 million, or 2% of annual global turnover, whichever is higher. This directive is a major shift in cyber risk management and supply chain security for entities operating energy, transport, banking, health, water, digital infrastructure, managed IT services, public administration and many more subsectors.
In this report, Intel 471 outlines how these entities in critical sectors affected by the European Commission’s NIS2 Directive can leverage premier CTI and intelligence-driven threat hunting to proactively mitigate digital threats and meet the directive’s higher risk management and incident reporting requirements. The report provides organizations with best practices to reduce cyber risk, anticipate threats, prioritise remediation of cloud resources and other IT assets, and continuously improve risk management measures to boost resilience and recovery.
“It is the right time to adopt NIS2 given today’s high stakes cybersecurity threat landscape. We’re seeing nation-state and cybercrime activity increasingly overlap, often driven by geopolitical events that create higher risks to all critical sectors in Europe. Defenders are overwhelmed by data and need timely intelligence that helps them focus on emerging threats, adversary tactics, and vulnerabilities that pose the greatest risk to them,” says Michael DeBolt, Chief Intelligence Officer at Intel 471. “Our unmatched human intelligence capability, patented malware emulation and tracking insights, and human-validated automated collection across thousands of threat actor communities help our customers in critical sectors across the globe understand their exposure and proactively mitigate digital risks. We go a step further by providing carefully curated intelligence-driven threat hunting content to rapidly identify and stop advanced threats in their tracks.”
Organisations impacted by NIS2 can utilise Intel 471’s unique CTI capabilities to improve security posture, reduce their attack surface and enhance resilience. “Being prepared with timely and trusted intelligence and threat hunting content that identifies adversarial techniques missed by traditional detection methods is critical for organisations to gain early visibility of emerging threats and proactively respond to cyber incidents. This intelligence-led approach to cyber defense and third party risk is at the heart of NIS2 directive,” says DeBolt.
NIS2’s broader scope than NIS1 dictates that many affected entities are urgently working to mature their CTI programs to better support their NIS2 cyber risk management strategies. The CTI Capability Maturity Model (CTI-CMM) — a free and vendor-neutral, “stakeholder-first” model, sponsored by Intel 471 and 27 other CTI industry expert peers from across the globe, assists organisations in building successful, impactful CTI programs.
For more details and to download the Intel 471 report, please visit: NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resilience
About Intel 471
Intel 471 empowers enterprises, government agencies, and other organizations to win the cybersecurity war using the real-time insights about adversaries, their relationships, threat patterns, and imminent attacks relevant to their businesses. The company’s platform collects, interprets, structures, and validates human-led, automation-enhanced intelligence, which fuels our external attack surface and advanced behavioral threat hunting solutions. Customers utilize this operationalized intelligence to drive a proactive response to neutralize threats and mitigate risk. Organizations across the globe leverage Intel 471’s world-class intelligence, our trusted practitioner engagement and enablement, and globally dispersed ground expertise as their frontline guardian against the ever-evolving landscape of cyber threats to fight the adversary — and win. Learn more at www.intel471.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105566758/en/
Contacts
Erica Stuchel
Intel471@w2comm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom